About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Experimental Ebola Drug Given to 2 American Ebola Patients is Hard to Make: Expert

by Thilaka Ravi on August 6, 2014 at 9:38 AM
Font : A-A+

Experimental Ebola Drug Given to 2 American Ebola Patients is Hard to Make: Expert

The experimental drug given to two American patients infected with Ebola virus is made from tobacco leaves and is hard to produce on a large scale, a leading US doctor said on Tuesday.

Known as ZMapp, the serum consists of three antibodies manufactured in modified tobacco leaves, which take weeks to grow.

Advertisement

It was reportedly rushed to US missionaries Kent Brantly and Nancy Writebol, who were stricken with Ebola while treating patients in Liberia.

Both have shown improvements in their health and are now being treated in isolation at an Atlanta, Georgia hospital.

"We cannot say right now that this drug is particularly promising," said Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases.
Advertisement

"The animal data are very good and the use of it in the two patients is suggestive that it may have a favorable effect, but since there are only two patients I think you have to be careful about making any definitive decision," he told AFP.

There is no drug or vaccine on the market against Ebola virus, which causes fever, vomiting, diarrhea, muscle aches and sometimes organ failure and hemorrhaging.

The ongoing outbreak in West Africa is the largest in history, having killed 887 of the more than 1,600 infected.

As for ZMapp, which was first identified as a drug candidate in January, there have been no safety tests yet in humans.

"As such, very little of the drug is currently available," the company said in a statement, adding that is working to scale up production as soon as possible.

ZMapp is a project of Mapp Biopharmaceutical, Inc. and LeafBio in San Diego, California, Defyrus Inc. in Toronto, Canada, the US government and the Public Health Agency of Canada.

Fauci said that the process of scaling up production will take time.

"It is going to take several months to get even a modest amount," he said.

"So yes, we do want to do clinical trials but the limiting factor is the number of treatment courses that are available."

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Congo Fever Ebola Virus Disease 

Recommended Reading
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have .....
Aid Volunteer Suffering from Ebola Virus to Return Back to US for Treatment
A charity aid group has confirmed that an American woman infected with the Ebola virus when working ...
WHO Says Ebola Outbreak Has So Far Claimed 887 Lives
Over 60 people died last week due to the recent outbreak of Ebola epidemic in West Africa, taking .....
$200 Million Pledged by World Bank for Fighting Ebola
The World Bank declared on Monday that it would provide up to $200 million to Guinea, Liberia and .....
Congo Fever
Crimean-Congo Hemorrhagic fever (CCHF) is a viral disease that affects people who are bitten by infe...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use